Pfizer Inc, Avidity Biosciences, Sarepta Therapeutics, Solid Biosciences, and Ultragenyx Pharmaceutical at Guggenheim Partners Healthcare Talks: Genomic Medicines & Rare Disease (Virtual) Transcript
All right, I think we're live. So good morning, and welcome to the Guggenheim Healthcare Talks, our signature Genomic Medicine & Rare Disease Conference Day. This is the second of our 9 panels, and this will primarily focus on Duchenne muscular dystrophy.
I am Debjit. I'm one of the senior analysts at Guggenheim, and joining us today is Michael Binks, the Vice President of Clinical Research from Pfizer; Sam Wadsworth, Clinical -- Chief Scientific Officer at Ultragenyx; Arthur Levin, Chief Scientific Officer at Avidity, Carl Morris, Chief Scientific Officer at Solid; and Ian Estepan, Chief Financial Officer at Sarepta.
Questions & Answers
So given we have a very packed panel, why don't I start first at Pfizer and more on sort of the challenge that we, on the outside are facing in trying to understand all the emerging data in the field. So even in younger patients, do
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
